Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Emerging Therapies for Patients with Advanced/Metastatic Pancreatic Adenocarcinoma

Pancreatic cancer is one of the common malignancies and one of the most lethal malignancies in the United States today.  Currently treatment option...

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Pancreatic cancer is one of the common malignancies and one of the most lethal malignancies in the United States today.  Currently treatment options are somewhat limited and often result in poor survival rates. 

    Join us as Dr. Philip discusses the currently available and emerging frontline and second-line therapies for patients with advanced and metastatic pancreatic ductal adenocarcinoma.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Philip A. Philip, MD, PhD, FRCP, FABC
    Professor of Oncology, Pharmacology and Medicine
    Kathryn Cramer Endowed Chair in Cancer Research
    Vice President of Medical Affairs
    Leader, GI and Neuroendocrine Tumors
    Department of Oncology
    Karmanos Cancer Institute
    Wayne State University
    Detroit, MI

    Dr. Philip is on the advisory boards of bioTheranostics, Caris, Celgene, EMD Serono, Halozyme, Lexicon and Merrimack; receives grants/research support from Acerta, Bayer, Celgene, Immunomedics, Incyte, Karyopharm, Lilly, Merck, Momenta, Novartis, Roche, Taiho and XBiotech; and is a speaker for Amgen, Celgene, Genentech and Novar

    Eileen M. O’Reilly, MD
    Associate Director, Clinical Research
    David M. Rubenstein Center for Pancreatic Cancer
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, NY

    Dr. O’Reilly receives consulting fees from Aduro Biotech Agios, Array, Aslan, Astellas Pharma US, Bayer, Blueprint, Boston Scientifc, BMS, Celgene, CASI, Celsion, Delcath, Eisai, EMD Sorono, Gilead, Halozyme, Integragen, Ipsen, Janssen, Merck, Merrimack, Momenta, New B Innovation, NewLink Genetics, Onxeo, Opsona, Pfizer, Roche, Sanofi-aventis, Servier, Silenseed, Sillajen, Sirtex, Vaxxim, Vicus Therapeutics, and Westhaven and contracted research for Amgen, Astra Zeneca, BMS, Bayer, CASI, Celgene, Chugai, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Myriad Genetics, OncoMed Pharmaceuticals Polaris Pharmaceuticals, Roche, and Vicus Therapeutics.


    • Sean T. Barrett, CHCP has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has nothing to disclose.
    • Jennifer Spear Smith, PhD has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review the latest clinical evidence on currently approved and emerging therapies for first- and second-line treatment of patients with advanced/metastatic PDAC
    • Identify factors (patient characteristics and adverse effects) that aid in clinical decision-making
    • Define optimal treatment algorithms to best sequence currently available and emerging treatments
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, oncology nurses, oncology nurse practitioners, and oncology physician assistants.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational programs based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merrimack Pharmaceuticals.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.